ACUTE MYELOID LEUKEMIA

This study looked at whether giving the antibiotic levofloxacin can prevent serious infections in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who are being treated with azacitidine. Infections are a major risk for these patients. The study enrolled…

This early-phase study tested the drug regorafenib in 16 adults with advanced blood cancers like acute myeloid leukemia that had stopped responding to other treatments. The main goal was to find the safest dose and see how the drug affects cancer-related cell signals. While not a…

This study tested a drug called guadecitabine along with a donor white blood cell infusion in 55 adults whose leukemia or myelodysplastic syndrome came back after a stem cell transplant. The goal was to see if this combination could help the body fight the cancer again. The treat…

This early-phase study tested two drugs, pevonedistat and decitabine, together in 12 people with high-risk acute myeloid leukemia (AML). The main goal was to find the safest dose and understand side effects. Researchers also looked at whether the combination could help control th…

This study tested whether a combination of the drug venetoclax plus a chemotherapy regimen called CACAG works better than the standard "3+7" chemotherapy for people newly diagnosed with acute myeloid leukemia (AML). The trial enrolled 200 patients aged 14 to 75. The main goal was…

This study tested a stem cell transplant from half-matched (haploidentical) family donors for people with various blood cancers. The treatment used a reduced-intensity chemotherapy and radiation regimen to prepare the body for the transplant. The goal was to see how many patients…

This study tested the drug dasatinib in 68 adults with several blood and bone marrow disorders, including certain leukemias, myelofibrosis, and mastocytosis. The goal was to see if dasatinib could help control these diseases and to check its safety. Results focused on how many pa…

This study looked at how well the drug venetoclax works for adults with newly diagnosed acute myeloid leukemia (AML) who cannot receive strong chemotherapy. About 120 participants in Switzerland and Austria took venetoclax pills daily as part of their normal care. Researchers tra…

This early-phase study tested a new drug called siremadlin added to two existing medicines (venetoclax and azacitidine) for adults with acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy. The study included 14 people whose cancer did not respond well …

This early-stage study tested whether adding two targeted drugs (gemtuzumab ozogamicin and midostaurin) to standard chemotherapy is safe for people with a specific type of acute myeloid leukemia (FLT3-mutated AML). 21 newly diagnosed adults took part. The goal was to find the bes…

This early-phase trial tested a combination of a cancer vaccine (CDX-1401), an immune booster (poly ICLC), chemotherapy (decitabine), and an immunotherapy drug (nivolumab) in 8 people with myelodysplastic syndrome (MDS) or low-blast acute myeloid leukemia (AML). The main goal was…

This study tested two different chemotherapy combinations as follow-up treatment (consolidation) in younger adults (ages 18-59) with newly diagnosed acute myeloid leukemia (AML) who achieved remission after initial therapy. The goal was to see which regimen better prevents the ca…

This early-phase study tested a combination of two drugs—veliparib and temozolomide—in 66 adults with acute leukemias that had come back or not responded to standard treatment. The goal was to find the safest dose and see how well the combination worked. Veliparib blocks a repair…

This study tested a new type of transplant for 25 people with acute myeloid leukemia or myelodysplastic syndromes who could not have a standard bone marrow transplant. Instead of using strong immune-suppressing drugs, doctors gave a small number of blood stem cells from a partial…

This study tested a new drug, gilteritinib, given together with standard chemotherapy for adults who were just diagnosed with acute myeloid leukemia (AML), a fast-growing blood cancer. The first part of the study looked for the safest dose of gilteritinib, and the second part che…

This study tested a new treatment for children and adults whose acute myeloid leukemia (AML) returned after a stem cell transplant. The treatment combined donor immune cells (lymphocytes) with specially trained natural killer (NK) cells designed to better attack the leukemia. The…

This study tested a two-drug combination (azacitidine and venetoclax) as an initial treatment for adults aged 60 and older with acute myeloid leukemia (AML) who had not received prior therapy. Participants first received both drugs together, and those who responded continued on v…

This early-stage study tested a new drug called JNJ-74856665 in 153 people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The main goal was to find safe doses and check for side effects. The drug works by blocking a protein that cancer cells need to grow.

This study tested a new treatment called CTX131 for adults with blood cancers (lymphoma or leukemia) that came back or didn't respond to standard therapy. CTX131 uses CRISPR gene editing to create donor immune cells that target a protein called CD70 on cancer cells. The goal was …

This early-stage study tested an oral drug called NTX-301 in 22 adults with certain blood cancers (MDS, AML, or CMML) that had not responded to prior treatment. The main goal was to see if the drug is safe and tolerable, while also checking for any signs that it might help contro…

This study tested whether adding the drug quizartinib to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia (AML) that does not have a FLT3 mutation. About 273 patients received either quizartinib or a placebo alongside their regular chemo. The main go…

This early-phase study tested a drug called ONC-201 in 20 people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who had recently received a stem cell transplant. The goal was to see if taking ONC-201 weekly for a year could help prevent the cancer f…

This early-phase study tested an experimental treatment called WU-NK-101 in 9 adults with acute myeloid leukemia that returned or didn't respond to standard therapy. The treatment uses specially grown natural killer cells from a healthy donor to attack the cancer. The main goals …

This study tested the drug enasidenib as a maintenance therapy for people with IDH2-mutant acute myeloid leukemia or chronic myelomonocytic leukemia after a stem cell transplant. The goal was to find the safest dose and see how well patients tolerated it. Twenty-three participant…

This study tested different combinations of immune-suppressing drugs to prevent graft-versus-host disease (GVHD) in 174 patients with blood cancers who received a stem cell transplant from an unrelated donor. The goal was to find the most effective approach to reduce severe GVHD,…

This early-phase study tested adding the cholesterol-lowering drug pitavastatin to the standard targeted therapy venetoclax for people with chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML). The main goal was to find a safe dose and check for side effects. Only 6…

This study tested a new form of chemotherapy called CPX-351 in 56 adults with a fast-growing blood cancer (acute myeloid leukemia) who were unlikely to respond to standard treatment. The drug combines two older chemo drugs inside a tiny fat bubble to help them work better togethe…

This study tested a combination of two drugs, bortezomib and lenalidomide, in 22 adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) came back after a stem cell transplant. The main goal was to find the safest dose and see if the combo could reduce cancer …

This early-phase study tested an oral drug called KPT-9274 in 16 adults whose acute myeloid leukemia (AML) had returned or not responded to prior treatments. The main goal was to find the safest dose and check for side effects. The study did not aim to cure the disease, but to ga…

This study tested whether adding 'off-the-shelf' natural killer (NK) immune cells from a donor could make stem cell transplants more effective for adults with high-risk forms of leukemia. The goal was to see if this combination was safe and could help prevent the cancer from comi…

This early study looked at how safe and effective a combination of two chemotherapy drugs (cytarabine and daunorubicin) is for adults newly diagnosed with acute myeloid leukemia (AML). The main goal was to see if the treatment caused heart problems, using MRI scans to monitor hea…

This study looked at whether covering the cost of blood transfusions would encourage people with blood cancers to enroll in hospice earlier. Many patients delay hospice because they need regular transfusions for symptom relief, which hospices often can't afford. The study offered…

This study looked at whether music therapy can ease fatigue and improve certain blood test results in people with acute myeloid leukemia who are receiving chemotherapy for the first time. Sixty adults took part, and researchers measured their fatigue levels and lab values like wh…

This study looked at whether adding a palliative care team (focused on symptom relief and emotional support) to usual cancer care improves quality of life for people with acute myeloid leukemia (AML). Researchers compared two groups of 160 hospitalized adults with high-risk AML. …

This study tested whether a telehealth program could help older adults (60+) with acute myeloid leukemia or myelodysplastic syndrome plan their future medical care. Researchers worked with 36 patients, their caregivers, and doctors to see if the program was easy to use and practi…

This early-phase trial tested adding atovaquone (a drug usually used to prevent pneumonia) to standard chemotherapy for children, teens, and young adults with newly diagnosed acute myeloid leukemia (AML). The main goals were to see how often doses had to be skipped due to side ef…

This study looked at 1,753 patients needing a bone marrow transplant for blood cancers or other serious blood disorders. It compared two approaches: first searching for a matched unrelated donor, or going straight to an alternative donor (like a half-matched family member). The g…

This study looked at 20 adults with acute myeloid leukemia (AML) who cannot have strong chemotherapy. They received a standard drug combination (azacitidine + venetoclax). Researchers measured venetoclax levels in the blood to see if they relate to how well the drug works and its…

This study aims to confirm that measuring two substances in the blood (FLT3L and IL-6) during the first round of chemotherapy can help predict how well patients with acute myeloid leukemia (AML) will do. Researchers will track 201 newly diagnosed AML patients across 25 centers in…

This study tested a tool called UR-GOAL to help older patients with acute myeloid leukemia (AML), their caregivers, and doctors communicate better about treatment choices. Fifteen patients aged 60 and older, along with their caregivers, used the tool and then gave feedback. The g…

This study looked at the tiny organisms (bacteria and fungi) living in the mouth and nose of 62 children with leukemia or those getting a bone marrow transplant. Researchers wanted to see how these germs change before and after chemotherapy. The goal was to learn more, not to tre…

This study looked at ovarian tissue from 9 young women with acute myeloid leukemia (AML) who had it frozen to preserve fertility before a stem cell transplant. The goal was to see if any leukemia cells remained in the tissue after the cancer was in remission. The findings help do…

This study tested a tool called UR-GOAL to help older patients with acute myeloid leukemia (AML) talk better with their doctors. 161 patients, caregivers, and doctors took part. The goal was to see if the tool improves shared decision-making and communication. This was a pilot st…

This study tested a personalized geriatric optimization plan (GO!) in 30 patients aged 60 and older who were getting a stem cell transplant for blood cancers or bone marrow failure. The plan included tailored changes to diet, sleep, activity, and medications. The goal was to see …

This study looked at people with a specific genetic form of acute myeloid leukemia (FLT3-mutated) whose cancer returned or didn't respond to treatment. Researchers compared those who took the drug gilteritinib after a stem cell transplant to those who received standard care, usin…